<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2350">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130567</url>
  </required_header>
  <id_info>
    <org_study_id>LP-128-CN101</org_study_id>
    <nct_id>NCT05130567</nct_id>
  </id_info>
  <brief_title>A Study of LP-128 Capsules in Healthy Subjects</brief_title>
  <official_title>A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Lupeng Pharmaceutical Company LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Lupeng Pharmaceutical Company LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and&#xD;
      Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial includes single dose and multiple dose phases. The single-dose phase included six&#xD;
      dose cohorts. Based on the safety and pharmacokinetic results of single-dose study,&#xD;
      approximately 2 doses will be selected to conduct multiple-dose study. The primary study&#xD;
      objectives are to evaluate the safety, tolerability, and pharmacokinetic characteristics&#xD;
      (including food effect and mass balance) of LP-128 capsules in healthy subjects after single&#xD;
      and multiple dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of LP-128 under fasted state</measure>
    <time_frame>Up to 7 and 21 days in Single-dose group and Multi-dose group, respectively</time_frame>
    <description>Plasma samples were collected at different points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal phase half-life (T1/2) of LP-128 under fasted state</measure>
    <time_frame>Up to 7 and 21 days in Single-dose group and Multi-dose group, respectively</time_frame>
    <description>Plasma samples were collected at different points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of LP-128 under fasted state</measure>
    <time_frame>Up to 7 and 21 days in Single-dose group and Multi-dose group, respectively</time_frame>
    <description>Plasma samples were collected at different points for pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of LP-128</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The incidence and severity of adverse events as assessed by NCI CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>excretion of LP-128 in urine</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Urine samples will be collected at different points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>excretion of LP-128 in feces</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>feces samples will be collected at different points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of LP-128 after meal</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Blood samples will be collected at different points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (T1/2) of LP-128 after meal</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Blood samples will be collected at different points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of LP-128 after meal</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Blood samples will be collected at different points for pharmacokinetic analysis</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Single-dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-dose Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-dose Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-dose Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LP-128 capsules</intervention_name>
    <description>Adaptive oral dosing with LP-128 capsules,with ascending or adjusted dosing based on the results of previous dosing.</description>
    <arm_group_label>Food Effect Experimental Group</arm_group_label>
    <arm_group_label>Multi-dose Experimental Group</arm_group_label>
    <arm_group_label>Single-dose Experimental Group</arm_group_label>
    <other_name>NWP-1080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Oral dosing with placebo capsules to match LP-128 capsules.</description>
    <arm_group_label>Food Effect Control Group</arm_group_label>
    <arm_group_label>Multi-dose Control Group</arm_group_label>
    <arm_group_label>Single-dose Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects have no history of serious digestive system, central nervous system,&#xD;
             cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal&#xD;
             and muscular system, blood system disease and cancer&#xD;
&#xD;
          -  Subjects (including partners) are willing to take effective contraception measures&#xD;
             during study and within 3 months after last dose&#xD;
&#xD;
          -  Male and female healthy subjects aged 18 to 55 years old&#xD;
&#xD;
          -  Male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg&#xD;
&#xD;
          -  Subjects able to understand and comply with study requirements&#xD;
&#xD;
          -  Willing to sign the informed consent and fully understand the content, process and&#xD;
             possible adverse reactions of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal vital signs, physical examination or laboratory tests with clinical&#xD;
             significance&#xD;
&#xD;
          -  Abnormal ECG or echocardiography with clinical significance&#xD;
&#xD;
          -  Positive screening for viral hepatitis, HIV and syphilis&#xD;
&#xD;
          -  Subjects who have taken any drugs or health care products within 14 or 28 days before&#xD;
             administration the study drug; or subjects who have consumed tea or alcohol-containing&#xD;
             food product within 24hrs before administration the study drug&#xD;
&#xD;
          -  Subjects who have a history of dysphagia or condition may affect drug absorption,&#xD;
             distribution, metabolism and excretion&#xD;
&#xD;
          -  Female subjects are breastfeeding or pregnant&#xD;
&#xD;
          -  Subjects who have a history of drug/alcohol/tobacco abuse&#xD;
&#xD;
          -  Subjects who have had a blood donation or massive blood loss within three months&#xD;
             before screening; or had major surgery within six months before screening&#xD;
&#xD;
          -  Subjects who have participated in other clinical trial within three months before&#xD;
             screening&#xD;
&#xD;
          -  Subjects have special dietary requirements or cannot tolerate a standard meal&#xD;
&#xD;
          -  Subjects who are not suitable for this trial based on the assessment of investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chongyuan Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Nanfang Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Shen, Ph.D</last_name>
    <phone>86571-81999616</phone>
    <email>yshen@lupengbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanFang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chongyuan Xu, MD, PhD</last_name>
      <phone>020-62787926</phone>
      <email>nfyygcp@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

